Plantronics, Inc. (PLT) Is At $63.11 Formed Wedge; Shorts at ASTELLAS PHARMA ORDINARY SHARES JAP (ALPMF) Raised By 41.08%

April 17, 2018 - By Winifred Garcia

Plantronics, Inc. (NYSE:PLT) Logo

ASTELLAS PHARMA INC ORDINARY SHARES JAP (OTCMKTS:ALPMF) had an increase of 41.08% in short interest. ALPMF’s SI was 5.50M shares in April as released by FINRA. Its up 41.08% from 3.90M shares previously. With 2,200 avg volume, 2502 days are for ASTELLAS PHARMA INC ORDINARY SHARES JAP (OTCMKTS:ALPMF)’s short sellers to cover ALPMF’s short positions. The SI to ASTELLAS PHARMA INC ORDINARY SHARES JAP’s float is 0.28%. The stock increased 0.34% or $0.05 during the last trading session, reaching $14.8. About shares traded. Astellas Pharma Inc. (OTCMKTS:ALPMF) has 0.00% since April 17, 2017 and is . It has underperformed by 11.55% the S&P500.

Plantronics, Inc. (PLT) formed wedge up with $66.90 target or 6.00% above today’s $63.11 share price. Plantronics, Inc. (PLT) has $2.03B valuation. The stock increased 1.45% or $0.9 during the last trading session, reaching $63.11. About 176,228 shares traded. Plantronics, Inc. (NYSE:PLT) has risen 2.93% since April 17, 2017 and is uptrending. It has underperformed by 8.62% the S&P500.

Astellas Pharma Inc., a pharmaceutical company, makes, markets, and imports and exports pharmaceutical products worldwide. The company has market cap of $29.40 billion. The firm offers Prograf and Advagraf/Graceptor/ASTAGRAF XL/Prograf XL, an immunosuppressant used to suppress organ transplant rejection; Vesicare, a treatment for overactive bladder; Harnal/Omnic, a blocking agent to treat the functional symptoms of benign prostatic hyperplasia; and Funguard/MYCAMIN, a candin-type antifungal agent. It has a 17.81 P/E ratio. It also provides Geninax, an oral new-type quinolone antibacterial agent; Celecox, an anti-inflammatory agent; Lipitor, a treatment for hypercholesterolemia; Micardis/Micombi/Micamlo, a treatment for hypertension; Gaster, a treatment for peptic ulcer and gastritis; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic agonist indicated for the treatment of overactive bladder; Eligard, a luteinizing hormone-releasing hormone agonist for the treatment of prostate cancer; XTANDI for the treatment of prostate cancer; and VESOMNI, a release tablet for the treatment of moderate to severe storage symptoms and voiding symptoms associated with benign prostatic hyperplasia in men who are not adequately responding to treatment with monotherapy.

Among 6 analysts covering Plantronics (NYSE:PLT), 3 have Buy rating, 0 Sell and 3 Hold. Therefore 50% are positive. Plantronics has $64.0 highest and $49 lowest target. $58.25’s average target is -7.70% below currents $63.11 stock price. Plantronics had 21 analyst reports since January 15, 2016 according to SRatingsIntel. The stock of Plantronics, Inc. (NYSE:PLT) has “Buy” rating given on Wednesday, November 1 by Roth Capital. As per Wednesday, May 4, the company rating was upgraded by Raymond James. As per Wednesday, January 31, the company rating was maintained by Northland Capital. The stock has “Overweight” rating by JP Morgan on Monday, January 18. The rating was maintained by Roth Capital on Thursday, September 28 with “Buy”. J.P. Morgan upgraded it to “Buy” rating and $6300 target in Thursday, June 1 report. The rating was maintained by Northland Capital with “Buy” on Monday, July 24. The rating was maintained by Northland Capital with “Buy” on Thursday, January 11. The firm has “Hold” rating by J.P. Morgan given on Friday, July 28. The firm has “Buy” rating given on Wednesday, January 31 by Roth Capital.

Since January 31, 2018, it had 0 buys, and 7 sales for $344,995 activity. The insider DEXHEIMER BRIAN S sold $30,950. The insider SARKAR SHANTANU sold $66,556.

Analysts await Plantronics, Inc. (NYSE:PLT) to report earnings on May, 7. They expect $0.62 EPS, up 1.64% or $0.01 from last year’s $0.61 per share. PLT’s profit will be $19.97 million for 25.45 P/E if the $0.62 EPS becomes a reality. After $0.77 actual EPS reported by Plantronics, Inc. for the previous quarter, Wall Street now forecasts -19.48% negative EPS growth.

Plantronics, Inc. (NYSE:PLT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: